Why Is REVOLUTION MEDICINES (RVMD) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 17, 2026 at 5:08 AM ET · reviewed against 1 wire stories
REVOLUTION MEDICINES (RVMD) is drawing unusual attention today. Our newswire has captured 1 story on RVMD across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 67/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
RVMD stock is moving higher today following a major multi-part clinical collaboration and regional licensing deal announced between Revolution Medicines and BeOne Medicines AG. The partnership, which involves evaluating drug combinations using BeOne’s clinical-stage oncology assets alongside Revolution’s RAS inhibitors, has sparked investor interest. The deal was disclosed in a Yahoo Finance headline and has positioned the company as a focal point for analysts covering the oncology space.
What Happened
Revolution Medicines and BeOne Medicines AG announced an agreement on August 10 to collaborate on clinical trials and explore regional licensing opportunities. The partnership leverages BeOne’s clinical-stage oncology assets with Revolution’s four clinical RAS(ON) inhibitors. This strategic move is expected to enhance the development potential of both companies’ drug pipelines. The deal has already drawn attention from analysts, with Truist Securities raising its price target to $231 and maintaining a Buy rating. RBC Capital and Wedbush also raised their price targets to $203 and $201 respectively, both maintaining Outperform ratings. The stock has seen recent volatility, with a 52-week high printed on August 17.
What The Data Shows
RVMD has printed five fresh 52-week highs in a single session on August 17. The stock has a market cap of $44.0B and remains unprofitable, with an EPS of -8.92 and a revenue decline of 97.2% year to date. Its beta of 1.40 suggests higher volatility than the broader market. Insider transactions in the past 90 days include 10 sell transactions totaling $25.0M, with the most recent on July 1. Former President Donald J. Trump also disclosed a sale of $50,001, $100,000 in May.
What To Watch
Revolution Medicines does not have a scheduled earnings date in the immediate future. Investors should monitor the breadth of analyst coverage and any updates on the progress of the clinical collaboration with BeOne Medicines AG.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RVMD · Aug 17 session (5-min) · +4.07% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 1 story · 67/100 bullish
The headlines behind the move
29d agoYahoo TopBULLISH 67M&A
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the August 10 agreement, the companies will combine select clinical-stage assets from BeOne with Revolution’s four clinical-stage RAS(ON) inhibitors to evaluate novel combination therapies for RAS-addicted cancers. Crucially, BeOne acquired exclusive rights […]
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →